PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript
PDS Biotechnology Corporation ( PDSB ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Frank Bedu-Addo - President, CEO & Director Lars Boesgaard - Principal Financial & Accounting Officer and CFO Kirk Shepard - Chief Medical Officer Conference Call Participants Thomas Johnson - Lifesci Advisors, LLC Mayank Mamtani - B. Riley Securities, Inc., Research Division Joseph Pantginis - H.C.
PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Frank K. Bedu-Addo - President, CEO & Director Kirk V.
PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Frank Bedu-Addo - CEO Lars Boesgaard - CFO Kirk Shepard - Chief Medical Officer Mike Moyer - IR, LifeSci Advisors Conference Call Participants Mayank Mamtani - B. Riley Securities Joseph Pantginis - H.C.
PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - CEO Kirk Shepard - Chief Medical Officer Lars Boesgaard - CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright Mayank Mamtani - B.
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for PDS Biotechnology (PDSB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer Lars Boesgaard - Chief Financial Officer Kirk Shepard - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Ali Rashidfarrokhi - B. Riley Robert LeBoyer - Noble Capital Markets Operator Good morning ladies and gentlemen and welcome to PDS Biotech's Third Quarter 2024 Results and Clinical Strategy Update Conference Call.
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PDS Biotechnology Corporation (PDSB) Clinical Program Update Conference Call (Transcript)
PDS Biotechnology Corporation (NASDAQ:PDSB ) Clinical Program Update Conference Call August 1, 2024 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer Kirk Shepard - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Joseph Pantginis - H.
